

Real-World Treatment Study of Koselugo (Selumetinib)

NCT06360406

Status RECRUITING
Sponsor AstraZeneca
Enrollment 200 participants

Key Eligibility Criteria

Inclusion (2)

- Patients treated with Koselugo (Selumetinib) under the approved label in South Korea
- Provision of signed and dated written informed consent by the patient or legally acceptable representative

Exclusion (2)

- Patients treated with Koselugo (Selumetinib) under the approved label in South Korea
- Provision of signed and dated written informed consent by the patient or legally acceptable representative

Locations (12 total)

Research Site, Busan, South Korea
Research Site, Chungcheongbuk-do, South Korea
Research Site, Daejeon, South Korea
... and 9 more locations